Axon Enterprise (NASDAQ:AXON) Stock Rating Reaffirmed as “Overweight” by Piper Sandler

Axon Enterprise (NASDAQ:AXON)‘s stock had its “overweight” rating reiterated by equities researchers at Piper Sandler in a research note issued to investors on Friday, MarketBeat.com reports. They presently have a $540.00 target price on the biotechnology company’s stock, down from their prior target price of $561.00. Piper Sandler‘s price objective indicates a potential upside of 72.52% from the stock’s current price.

A number of other analysts also recently issued reports on AXON. Royal Bank Of Canada reiterated an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, July 21st. Craig Hallum lowered shares of Axon Enterprise from a “buy” rating to a “hold” rating and set a $390.00 price objective on the stock. in a research report on Friday. Zacks Research cut shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 3rd. The Goldman Sachs Group reduced their target price on shares of Axon Enterprise from $715.00 to $675.00 and set a “buy” rating for the company in a report on Monday, September 21st. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Axon Enterprise in a research report on Monday, November 2nd. Thirteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $631.35.

Axon Enterprise Stock Down 18.2%

Shares of Axon Enterprise stock opened at $313.00 on Friday. The firm has a market cap of $25.43 billion, a PE ratio of 100.32, a P/E/G ratio of 5.95 and a beta of 1.48. The business’s 50 day simple moving average is $441.53 and its 200 day simple moving average is $475.20. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. Axon Enterprise has a 52-week low of $307.00 and a 52-week high of $665.07.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.17). Axon Enterprise had a return on equity of 3.95% and a net margin of 7.56%. The firm had revenue of $908.55 million for the quarter, compared to analyst estimates of $934.33 million. During the same period last year, the company earned $1.17 EPS. The company’s revenue was up 27.8% compared to the same quarter last year. On average, analysts predict that Axon Enterprise will post 2.10 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $508.99, for a total transaction of $5,089,900.00. Following the completion of the transaction, the chief executive officer directly owned 3,118,012 shares of the company’s stock, valued at approximately $1,587,036,927.88. This represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey C. Kunins sold 9,605 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $626.70, for a total value of $6,019,453.50. Following the completion of the transaction, the insider owned 97,761 shares of the company’s stock, valued at approximately $61,266,818.70. This represents a 8.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 37,397 shares of company stock worth $21,234,034 in the last three months. Insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

Institutional investors and hedge funds have recently made changes to their positions in the stock. M & L Capital Management Ltd acquired a new stake in shares of Axon Enterprise in the 3rd quarter valued at approximately $30,000. Keating Financial Advisory Services Inc. bought a new position in shares of Axon Enterprise in the second quarter valued at $31,000. Wealth Enhancement Trust Services Inc. bought a new position in shares of Axon Enterprise in the third quarter valued at $33,000. Putney Financial Group LLC acquired a new position in Axon Enterprise during the third quarter worth $36,000. Finally, Washington Trust Advisors Inc. increased its holdings in Axon Enterprise by 1,300.0% during the second quarter. Washington Trust Advisors Inc. now owns 70 shares of the biotechnology company’s stock worth $39,000 after buying an additional 65 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q3 revenue reached a record $909 million, up 28% year over year, while software and services revenue rose 43%. Axon also reported AI annual recurring revenue above $100 million, signaling continued demand for its software and AI offerings. Axon Q3 results
• Neutral Sentiment: Axon committed an additional $1.2 billion to drone maker Skydio, bringing its stake to 37% and making it Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move could expand Axon’s Drone as First Responder business, but its scale also raises investment and execution risks. Reuters: Axon invests in Skydio
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million fell short of analyst expectations. Axon’s 2026 revenue forecast was reduced to $3.6 billion from a consensus of about $3.7 billion; its Q4 revenue guidance also came in below estimates. The company cited delays in federal counter-drone projects, while margin pressure added to concerns. Zacks: Q3 miss and outlook
• Negative Sentiment: Several analysts lowered price targets after the results, and Craig Hallum downgraded AXON from Buy to Hold, adding to pressure on investor sentiment. Benzinga: analyst forecast changes
• Negative Sentiment: A class-action lawsuit over Axon’s license-plate surveillance practices is a potential additional legal and reputational overhang. Class-action announcement

Axon Enterprise Company Profile

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals.

The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Founded in 1993 as TASER International, the company adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into connected devices and software.